|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
antineoplastic agent
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XC14
|
|
gptkbp:biosimilar
|
no (as of 2024)
|
|
gptkbp:brand
|
gptkb:Kadcyla
|
|
gptkbp:CASNumber
|
1018448-65-1
|
|
gptkbp:chemicalClass
|
monoclonal antibody conjugate
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
hypersensitivity to trastuzumab emtansine
|
|
gptkbp:developer
|
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:eliminatedIn
|
hepatic
|
|
gptkbp:form
|
lyophilized powder for injection
|
|
gptkbp:halfLife
|
3.5-4 days
|
|
gptkbp:hasComponent
|
gptkb:DM1_(emtansine)
gptkb:trastuzumab
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trastuzumab emtansine
|
|
gptkbp:indication
|
gptkb:HER2-positive_breast_cancer
metastatic breast cancer
early breast cancer (adjuvant)
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
delivers cytotoxic agent to cancer cells
targets HER2 receptor
|
|
gptkbp:MedlinePlusID
|
a613032
|
|
gptkbp:metabolism
|
proteolytic enzymes
|
|
gptkbp:molecularWeight
|
~148 kDa
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
DB05919
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:RxNorm
|
1366972
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
peripheral neuropathy
thrombocytopenia
increased liver enzymes
|
|
gptkbp:target
|
gptkb:HER2_protein
|
|
gptkbp:UNII
|
P8I9DV1DLW
|
|
gptkbp:usedFor
|
HER2-positive tumors
|
|
gptkbp:usedIn
|
oncology
|
|
gptkbp:bfsParent
|
gptkb:DM1_(emtansine)
|
|
gptkbp:bfsLayer
|
7
|